1. When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?

   • L. S. Freedman
   • P. Workman

   Original Articles Pages: 95 - 103

2. Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug matabolism

   • Sandor Kerpel-Fronius
   • Jaap Verwey
   • Herbert M. Pinedo

   Original Articles Pages: 104 - 108

3. The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol

   • S. Kerpel-Fronius
   • V. Erdélyi-Tóth
   • B. Kanyár

   Original Articles Pages: 109 - 113

4. Flavone acetic acid: a nonlinear pharmacokinetic model

   • Alain Gouyette
   • David J. Kerr
   • Mike Soukop

   Original Articles Pages: 114 - 119

5. Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog

   • Joanne I. Brodfuehrer
   • Tracy J. Wilke
   • Garth Powis

   Original Articles Pages: 120 - 125

6. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor)oxidoreductase

   • John J. Schlager
   • Garth Powis

   Original Articles Pages: 126 - 130

7. Variability of tumor response to chemotherapy II. Contribution of tumor heterogeneity

   • L. Simpson-Herren
   • P. E. Noker
   • S. D. Wagoner

   Original Articles Pages: 131 - 136

8. The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man

   • V. Skalski
   • J. Rivas
   • W. Feindel

   Original Articles Pages: 137 - 140

9. A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma — intensive two-phase chemotherapy

   • Central Lymphoma Group
   • Nicholas S. A. Stuart
   • Adrian V. Simmons

   Original Articles Pages: 141 - 146

10. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate

    • Brenda J. Foster
    • Karen R. Grotzinger
    • Thomas C. Hamilton

    Original Articles Pages: 147 - 152

11. The hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats

    • T. Ducastelle
    • G. Raguenez-Viotte
    • J. P. Fillastre

    Original Articles Pages: 153 - 162

12. Correction of altered plasma membrane potentials

    • Bharathi Vayuvegula
    • Lewis Slater
    • Sudhir Gupta

    Original Articles Pages: 163 - 168

13. HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma

    • R. Liang
    • D. Todd
    • T. K. Chan

    Original Articles Pages: 169 - 171

14. Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer

    • Francesco Boccardo
    • Andrea Decensi
    • Luciano Giuliani

    Original Articles Pages: 172 - 174

15. Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites

    • P. O. Uadia
    • A. H. Blair
    • T. Ghose

    Short Communication Pages: 175 - 177

16. Potentiation of cis-diamminedichloroplatinum nephrotoxicity by amikacin in rats

    • Hermina T. M. Jongejan
    • Abraham P. Provoost
    • Jan C. Molenaar

    Short Communication Pages: 178 - 180

17. Potentiation of anticoagulant effect of coumadin by 5-bromo-2′-deoxyuridine (BUDR)

    • Sharon E. Oster
    • H. Jeffrey Lawrence

    Letter to the Editors Pages: 181 - 181